Home Medizin Neues Arzneimittel-Screening-System hilft dabei, vielversprechende Angriffspunkte für die Behandlung von Bauchspeicheldrüsenkrebs zu entdecken

Neues Arzneimittel-Screening-System hilft dabei, vielversprechende Angriffspunkte für die Behandlung von Bauchspeicheldrüsenkrebs zu entdecken

von NFI Redaktion

A recent study conducted by Weill Cornell Medicine researchers has discovered a promising target for future pancreatic cancer treatments using a drug screening system that models cancer using laboratory-grown tissues known as organoids.

The study, published on December 26 in Stem Cell, involved testing over 6,000 compounds on organoids that contained a common pancreatic cancer-inducing mutation. The researchers identified a compound, an existing heart medication called Perhexilinmaleat, that significantly suppressed the growth of the organoids.

The study’s co-senior author, Dr. Todd Evans, stated, “Our results identify hyperactive cholesterol synthesis as a vulnerability that can be targeted in most pancreatic cancer types.“

Dr. Shuibing Chen, co-first author of the study, emphasized the value of using genetically defined organoids for modeling cancer and discovering new treatment strategies.

The study also revealed that Cholesterin, an essential component for cell growth and survival, could serve as a potential target for effective new treatment strategies against pancreatic cancer.

The research team plans to use Perhexilinmaleat as a starting point for developing a refined pancreatic cancer drug candidate and as a laboratory tool to further study cholesterol synthesis in pancreatic cancer and other cancers.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.